March 12, 2025

Kinvard Bio

Kinvard is a preclinical biotech with an IV/oral compound targeting gram-negative and positive pathogens, leveraging technology from Harvard University and non-dilutive funding from CARB-X.

January 30, 2025

Clarametyx

Clarametyx is a clinical-stage biotech developing anti-biofilm antibodies for cystic fibrosis and other respiratory infections

December 12, 2024

Orthobond

Orthobond has developed a coating for medical device implants to prevent biofilm formation and infection from orthopedic surgery.

December 12, 2024

Endolytix

Endolytix is using enzymes from bacteriophages to target antibiotic resistant nontuberculous mycobacteria (NTM) that cause chronic lung disease.